Replimune (REPL) Share-based Compensation (2017 - 2026)
Replimune (REPL) reported Share-based Compensation of $8.1 million for Q1 2026, down 1.87% on a YoY basis from $8.3 million in Q1 2025, and up 15.3% sequentially from $7.0 million in Q4 2025.
Replimune (REPL) Share-based Compensation (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Share-based Compensation data on file, last reported at $8.1 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 1.87% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $32.3 million (down 7.91% YoY), and the FY2026 full-year result was $32.3 million, down 7.91% from the prior year.
- Share-based Compensation rose to $8.1 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.5 million in Q2 2024 to a low of $5.8 million in Q1 2022.
- A 5-year average of $8.0 million and a median of $8.2 million in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 66.27% in 2022 and dropped 18.43% in 2025, its largest moves.
- Tracing REPL's Share-based Compensation over 5 years: stood at $7.0 million in 2022, then grew by 17.33% to $8.2 million in 2023, then gained by 4.84% to $8.6 million in 2024, then retreated by 18.43% to $7.0 million in 2025, then rose by 15.3% to $8.1 million in 2026.
- Business Quant data shows REPL's Share-based Compensation at $8.1 million in Q1 2026, $7.0 million in Q4 2025, and $8.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 8.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.13 Mn |
| Mar 31, 2026 | 8.13 Mn |
| Dec 31, 2025 | 7.05 Mn |
| Dec 31, 2025 | 7.05 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Dec 31, 2023 | 8.24 Mn |
| Dec 31, 2023 | 8.24 Mn |